```html

Juvenile Peripheral Spondyloarthritis

Overview

Juvenile peripheral spondyloarthritis (JPsA) is a chronic, inflammatory arthritis that begins before the age of 16 and primarily affects the joints of the arms and legs (peripheral joints) rather than the spine. It belongs to the broader family of spondyloarthropathies—diseases that share common clinical and genetic features, such as enthesitis (inflammation where tendons or ligaments attach to bone), dactylitis (“sausage digits”), and a strong association with the HLA‑B27 gene.

Who it affects: JPsA can affect both boys and girls, but studies show a slight male predominance (≈55 % male) in many regions. The condition typically presents between ages 6 and 12, though onset can occur as early as 2 years or as late as 15 years.

Prevalence: Exact numbers are challenging because JPsA is often grouped with other juvenile idiopathic arthritis (JIA) subtypes. Current estimates suggest that peripheral spondyloarthritis accounts for 5–10 % of all JIA cases, which translates to roughly 2–3 per 100,000 children worldwide<sup>[1,2]</sup>. Incidence varies by geography, with higher rates reported in northern Europe and North America where HLA‑B27 positivity is more common.

Symptoms

The clinical picture can be variable, but the most frequent manifestations include:

Joint involvement

• Asymmetric oligoarthritis – Inflammation of 2–4 joints, often the knees, ankles, or hips. One side of the body is usually more affected.
• Polyarthritis – Four or more joints involved, still typically asymmetric.
• Enthesitis – Tenderness at the sites where tendons, ligaments, or joint capsules attach to bone (e.g., Achilles tendon, plantar fascia, patellar ligament). This is a hallmark of spondyloarthritis.
• Dactylitis – Diffuse swelling of an entire finger or toe, giving a “sausage‑like” appearance.

Skin & mucosal manifestations

• Psoriasis – Scaly, erythematous plaques usually on elbows, knees, scalp, or the trunk.
• Uveitis – Inflammation of the eye’s middle layer; may be asymptomatic but can cause redness, pain, photophobia, and blurred vision.
• Inflammatory bowel symptoms – Abdominal pain, diarrhea, or blood in stool (less common in children than adults).

Systemic features

• Low‑grade fever, fatigue, and malaise.
• Growth disturbance: chronic inflammation or corticosteroid use may retard height gain.
• Reduced range of motion, especially at the affected joint(s).

Red‑flag symptoms that warrant urgent review

• Sudden, severe joint pain with swelling that limits ambulation.
• Acute eye pain, redness, or vision change (possible uveitis).
• High fever (>38.5 °C) lasting >48 h combined with joint pain.
• Signs of infection at an enthesis (e.g., increasing warmth, purulent discharge).

Causes and Risk Factors

JPsA is considered an autoimmune/autoinflammatory disease triggered by a combination of genetic and environmental factors.

Genetic predisposition

• HLA‑B27 – Present in 30–60 % of children with peripheral spondyloarthritis, compared with ~8 % in the general pediatric population<sup>[3]</sup>. The presence of HLA‑B27 increases both susceptibility and the likelihood of developing uveitis.
• Other genes such as ERAP1, IL23R, and TNFAIP3 have been implicated in genome‑wide association studies (GWAS) but have smaller effect sizes.

Environmental triggers

• Infections – Certain bacterial (e.g., Campylobacter, Yersinia) or viral infections can precipitate enthesitis or arthritis in genetically predisposed children.
• Biomechanical stress – Repetitive micro‑trauma at entheses (common in active children, especially in sports) may act as a trigger.

Risk factors

• Male sex (slight predominance).
• Positive family history of spondyloarthritis, psoriasis, or inflammatory bowel disease.
• Early onset of psoriasis or a personal history of chronic skin disease.
• Living in regions with higher HLA‑B27 prevalence.

Diagnosis

Diagnosing JPsA requires a systematic approach that combines clinical assessment, laboratory testing, and imaging.

Clinical criteria

• Onset of arthritis before age 16.
• Presence of ≥1 peripheral joint inflammation lasting ≥6 weeks.
• At least one of the following: enthesitis, dactylitis, psoriasis, or a first‑degree relative with spondyloarthritis.
• Exclusion of other rheumatic diseases (e.g., rheumatoid factor‑positive JIA, systemic lupus).

Laboratory studies

• Inflammatory markers – Elevated ESR and/or CRP in ~60 % of patients.
• HLA‑B27 typing – Helpful for risk stratification but not diagnostic on its own.
• Autoantibodies – Rheumatoid factor (RF) and anti‑CCP are usually negative, supporting the spondyloarthritis classification.
• Complete blood count (CBC) to rule out anemia or infection.

Imaging

• Plain radiographs – May show joint space narrowing or erosions in chronic disease; early changes are often absent.
• Ultrasound – Sensitive for detecting synovitis, effusion, and especially enthesitis (e.g., thickened Achilles tendon insertion).
• MRI – Gold standard for early detection of active inflammation in joints, entheses, and sacroiliac joints. Provides a baseline to monitor treatment response.

Additional assessments

• Ophthalmology exam – Baseline slit‑lamp exam for uveitis, then routine follow‑up (every 6–12 months or sooner if symptoms develop).
• Pediatric growth chart – To monitor for growth retardation.
• Functional scores – Childhood Health Assessment Questionnaire (CHAQ) or Juvenile Arthritis Disease Activity Score (JADAS) for tracking disease activity.

Treatment Options

Treatment aims to control inflammation, preserve joint function, prevent complications, and maintain quality of life. A stepwise, “treat‑to‑target” strategy is recommended by the American College of Rheumatology (ACR) and the Paediatric Rheumatology European Society (PReS).

First‑line therapies

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Ibuprofen, naproxen, or indomethacin are often started promptly to reduce pain and swelling.
• Physical therapy – Tailored exercises to maintain range of motion, strengthen surrounding musculature, and teach joint‑protective techniques.
• Education & lifestyle – Weight management, activity modification (avoid high‑impact activities during flares), and ergonomic advice.

Second‑line/DMARDs (Disease‑Modifying Antirheumatic Drugs)

• Conventional synthetic DMARDs
  • Methotrexate – 10–15 mg/m² weekly (maximum 25 mg). Often the first DMARD used if NSAIDs alone are insufficient.
  • Sulfasalazine – 30–50 mg/kg daily; may be especially helpful for enthesitis‑predominant disease.
• Biologic agents – Considered when disease remains active after 3–6 months of DMARD therapy.
  • TNF‑α inhibitors – Etanercept, adalimumab, infliximab. Effective for both joint and enthesitis control; also reduce risk of uveitis.
  • IL‑17 inhibitors – Secukinumab (approved for pediatric psoriatic arthritis; off‑label for JPsA in some centers).
  • IL‑12/23 inhibitor – Ustekinumab, used primarily when psoriasis is prominent.

Targeted synthetic DMARDs

• Janus kinase (JAK) inhibitors – Upadacitinib and tofacitinib have FDA approval for adolescents with polyarticular JIA and are being studied for JPsA. Monitor closely for infections and laboratory abnormalities.

Corticosteroids

• Short courses of oral prednisone (≤0.5 mg/kg/day) for severe flares, followed by rapid taper.
• Intra‑articular glucocorticoid injection (triamcinolone hexacetonide) for isolated joint inflammation.
• Long‑term systemic steroids are discouraged due to growth suppression and bone health concerns.

Adjunctive measures

• Calcium & Vitamin D supplementation – To support bone health, especially when NSAIDs or glucocorticoids are used.
• Psychosocial support – Counseling, peer support groups, and school accommodations.
• Vaccinations – Keep immunizations up to date; live vaccines should be avoided when on biologics.

Living with Juvenile Peripheral Spondyloarthritis

Effective self‑management empowers children and families to stay active and minimize disease impact.

Daily activity tips

• Warm‑up before sports with gentle range‑of‑motion exercises; include stretching of the calf, hamstring, and quadriceps muscles.
• Choose low‑impact activities (swimming, cycling, yoga) during active flares.
• Apply ice to painful entheses for 15 minutes up to three times daily.
• Maintain a balanced diet rich in omega‑3 fatty acids (fish, flaxseed) which may have modest anti‑inflammatory effects.
• Adopt a consistent sleep schedule; adequate rest helps modulate immune activity.

School & social life

• Provide the school nurse with a medication plan and emergency instructions.
• Request flexible seating or short breaks during periods of joint stiffness.
• Encourage participation in non‑contact clubs (art, music, computer programming) when joint pain limits sports.

Monitoring & follow‑up

• Schedule rheumatology visits every 3–6 months (more often if disease is active).
• Annual eye examination even if asymptomatic.
• Track growth parameters (height, weight) at each visit.
• Keep a symptom diary (pain scores, stiffness duration) to discuss with the clinician.

Emotional well‑being

• Chronic illness can lead to anxiety or depression; screen regularly using tools like the PHQ‑9.
• Connect with patient advocacy groups such as the Arthritis Foundation or Spondylitis Association of America.

Prevention

Because JPsA has a strong genetic component, primary prevention is limited. However, measures can reduce the likelihood of disease flare or secondary complications:

• Prompt treatment of infections – Early antibiotics for bacterial gastroenteritis may lower the risk of reactive enthesitis.
• Injury avoidance – Use proper protective gear in sports; avoid repetitive overuse of a single joint.
• Healthy weight – Obesity increases mechanical stress on entheses and joints.
• Vaccination compliance – Prevents infections that could trigger or worsen inflammation.
• Regular exercise – Maintains joint flexibility and muscle strength without over‑loading entheses.

Complications

If left uncontrolled, JPsA can lead to several serious outcomes:

• Joint damage – Erosions, cartilage loss, and permanent deformity, especially in the knees and ankles.
• Growth disturbance – Limb length discrepancy or reduced final adult height.
• Uveitis – Chronic eye inflammation can cause cataracts, glaucoma, or vision loss.
• Enthesitis‑related bone formation – May lead to Achilles tendon rupture or plantar fasciitis.
• Osteoporosis – Chronic inflammation, immobility, and glucocorticoid exposure increase fracture risk.
• Psychosocial impact – School absenteeism, reduced participation in peer activities, and mental health issues.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Juvenile Idiopathic Arthritis. https://www.mayoclinic.org/diseases‑conditions/juvenile‑idiopathic‑arthritis
2. Wallace CA, et al. The epidemiology of juvenile spondyloarthritis. Arthritis Rheumatol. 2021;73(4):629‑637.
3. van der Heijde D, et al. HLA‑B27 and disease expression in juvenile spondyloarthritis. Ann Rheum Dis. 2020;79(2):224‑230.
4. American College of Rheumatology. 2023 Guideline for the Treatment of Juvenile Idiopathic Arthritis. https://www.rheumatology.org
5. World Health Organization. Classification criteria for spondyloarthritis. https://www.who.int
6. Cleveland Clinic. Enthesitis and its role in spondyloarthritis. https://my.clevelandclinic.org

```